Table 1.

PICOS criteria.

Domain	Eligible	Ineligible
Population	Adult patients with a confirmed diagnosis of one of the following immunology diseases: • Asthma • Atopic dermatitis • Rheumatoid arthritis • Systemic lupus erythematosus • Ulcerative colitis	• Patients without a confirmed diagnosis of one of the immunology diseases of interest • Children (aged ≤17 years)
Intervention	Any approved or investigational therapy that would be considered (or has the potential to be considered) an immune-resolution therapy including PD-1 agonists, IL-2 conjugates, CD200R agonists, Treg modulators, and BTLA agonists	• Surgical interventions • Alternative medicine
Comparators	Any or none	NA
Outcomes	• Any outcome relating to immune resolution • Expert opinion on immune-resolution outcomes expected in the future	Surrogate endpoints not definitively linked to immune resolution
Study design	• Interventional trials • Expert opinions	Reviews reporting secondary data
Time frame	2013-present	Publications before 2013
Language	English	Non-English

BTLA, B- and T-lymphocyte attenuator; CD200R, CD200 receptor; IL-2, interleukin-2; NA, not applicable; PD-1, programmed cell death protein-1; Treg, regulatory T-cells.